A detailed history of Rhumbline Advisers transactions in Celcuity Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 32,464 shares of CELC stock, worth $510,983. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,464
Previous 25,415 27.74%
Holding current value
$510,983
Previous $548,000 3.1%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$14.1 - $20.78 $99,390 - $146,478
7,049 Added 27.74%
32,464 $531,000
Q1 2024

May 09, 2024

BUY
$13.74 - $21.6 $27,672 - $43,502
2,014 Added 8.61%
25,415 $548,000
Q4 2023

Feb 08, 2024

BUY
$8.7 - $15.02 $25,473 - $43,978
2,928 Added 14.3%
23,401 $340,000
Q3 2023

Nov 09, 2023

BUY
$8.96 - $10.75 $6,397 - $7,675
714 Added 3.61%
20,473 $187,000
Q2 2023

Aug 08, 2023

BUY
$9.39 - $12.18 $185,537 - $240,664
19,759 New
19,759 $216,000

Others Institutions Holding CELC

About Celcuity Inc.


  • Ticker CELC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,941,300
  • Market Cap $235M
  • Description
  • Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...
More about CELC
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.